(Avibactam sodium + ceftazidime) is a Small Molecule owned by Pfizer, and is involved in 40 clinical trials, of which 31 were completed, 8 are ongoing, and 1 is planned.

Ceftazidime binds to the penicillin-binding proteins (PBPs) of bacterial cell wall which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall. This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

Avibactam is a non-beta-lactam beta-lactamase inhibitor that inactivates some beta-lactamases

The revenue for (Avibactam sodium + ceftazidime) is expected to reach a total of $11.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Avibactam sodium + ceftazidime) NPV Report.

(Avibactam sodium + ceftazidime) is currently owned by Pfizer.

(Avibactam sodium + ceftazidime) Overview

Avibactam and Ceftazidime (Avycaz / Zavicefta / Sifuto / Torgena / Ryambic) is a fixed dose combination drug. Ceftazidime is a third generation semisynthetic cephalosporin. It is formulated as powder for solution for intravenous route of administration. It is indicated for the treatment of complicated intra abdominal infections, used in combination with metronidazole and complicated urinary tract infections including pyelonephritis. Zavicefta indicated for the treatment of adult patients suffering from complicated intra-abdominal infections (cIAI); Complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); and, the treatment of aerobic Gram-negative infections in adult patients who have limited treatment options, treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older, for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) in patients 3 months to less than 18 years of age.

It is under development for the treatment of nosocomial pneumonia and ventilator associated pneumonia. It was also under development for urinary tract infections, complicated intra-abdominal infections, pyelonephritis, ventilator associated pneumonia and hospital acquired pneumonia in China. It was administered through oral route. 

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – (Avibactam sodium + ceftazidime)

Report Segments
  • Innovator (NME)
Drug Name
  • (Avibactam sodium + ceftazidime)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.